Tags : KEYNOTE-240

Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-240 Study

Vartika Singh February 21, 2019

Shots: The P-III KEYNOTE-240 Study involves assessing of Keytruda (200mg, q3w) vs PBO in 413 patients with 1L advance HCC The study resulted in unmet 1EPs & 2EPs as OS, […]readmore

Tags : KEYNOTE-240

Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-240 Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : KEYNOTE-240

﻿Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-240 Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-240 Study